293 related articles for article (PubMed ID: 19576239)
1. Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue.
McDowell CL; Bryan Sutton R; Obermann WM
Int J Biol Macromol; 2009 Oct; 45(3):310-4. PubMed ID: 19576239
[TBL] [Abstract][Full Text] [Related]
2. A comparison of Hsp90alpha and Hsp90beta interactions with cochaperones and substrates.
Taherian A; Krone PH; Ovsenek N
Biochem Cell Biol; 2008 Feb; 86(1):37-45. PubMed ID: 18364744
[TBL] [Abstract][Full Text] [Related]
3. Domain-mediated dimerization of the Hsp90 cochaperones Harc and Cdc37.
Roiniotis J; Masendycz P; Ho S; Scholz GM
Biochemistry; 2005 May; 44(17):6662-9. PubMed ID: 15850399
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of hsp90 isoforms in colorectal cancer cells and its association with tumour progression.
Milicevic Z; Bogojevic D; Mihailovic M; Petrovic M; Krivokapic Z
Int J Oncol; 2008 Jun; 32(6):1169-78. PubMed ID: 18497978
[TBL] [Abstract][Full Text] [Related]
5. Concerted actions of multiple transcription elements confer differential transactivation of HSP90 isoforms in geldanamycin-treated 9L rat gliosarcoma cells.
Chao CC; Sun FC; Wang CH; Lo CW; Chang YS; Chang KC; Chang MD; Lai YK
J Cell Biochem; 2008 Jul; 104(4):1286-96. PubMed ID: 18320580
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction.
Thomas M; Harrell JM; Morishima Y; Peng HM; Pratt WB; Lieberman AP
Hum Mol Genet; 2006 Jun; 15(11):1876-83. PubMed ID: 16644868
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of Hsp90 isoforms in geldanamycin-treated 9L cells.
Chang YS; Lo CW; Sun FC; Chang MD; Lai YK
Biochem Biophys Res Commun; 2006 May; 344(1):37-44. PubMed ID: 16630568
[TBL] [Abstract][Full Text] [Related]
8. The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins.
McLaughlin SH; Sobott F; Yao ZP; Zhang W; Nielsen PR; Grossmann JG; Laue ED; Robinson CV; Jackson SE
J Mol Biol; 2006 Feb; 356(3):746-58. PubMed ID: 16403413
[TBL] [Abstract][Full Text] [Related]
9. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
Prince TL; Kijima T; Tatokoro M; Lee S; Tsutsumi S; Yim K; Rivas C; Alarcon S; Schwartz H; Khamit-Kush K; Scroggins BT; Beebe K; Trepel JB; Neckers L
PLoS One; 2015; 10(10):e0141786. PubMed ID: 26517842
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors.
Li CF; Huang WW; Wu JM; Yu SC; Hu TH; Uen YH; Tian YF; Lin CN; Lu D; Fang FM; Huang HY
Clin Cancer Res; 2008 Dec; 14(23):7822-31. PubMed ID: 19047110
[TBL] [Abstract][Full Text] [Related]
11. Middle domain of human Hsp90 isoforms differentially binds Aha1 in human cells and alters Hsp90 activity in yeast.
Synoradzki K; Bieganowski P
Biochim Biophys Acta; 2015 Feb; 1853(2):445-52. PubMed ID: 25486457
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 and Cdc37 -- a chaperone cancer conspiracy.
Pearl LH
Curr Opin Genet Dev; 2005 Feb; 15(1):55-61. PubMed ID: 15661534
[TBL] [Abstract][Full Text] [Related]
13. Evidence for chaperone heterocomplexes containing both Hsp90 and VCP.
Prince T; Shao J; Matts RL; Hartson SD
Biochem Biophys Res Commun; 2005 Jun; 331(4):1331-7. PubMed ID: 15883021
[TBL] [Abstract][Full Text] [Related]
14. Role of the cochaperone Tpr2 in Hsp90 chaperoning.
Moffatt NS; Bruinsma E; Uhl C; Obermann WM; Toft D
Biochemistry; 2008 Aug; 47(31):8203-13. PubMed ID: 18620420
[TBL] [Abstract][Full Text] [Related]
15. Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol.
Millson SH; Truman AW; Rácz A; Hu B; Panaretou B; Nuttall J; Mollapour M; Söti C; Piper PW
FEBS J; 2007 Sep; 274(17):4453-63. PubMed ID: 17681020
[TBL] [Abstract][Full Text] [Related]
16. Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias.
Wang W; Ji P; Steffen B; Metzger R; Schneider PM; Halfter H; Schrader M; Berdel WE; Serve H; Müller-Tidow C
Acta Biochim Biophys Sin (Shanghai); 2005 Mar; 37(3):173-80. PubMed ID: 15756419
[TBL] [Abstract][Full Text] [Related]
17. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Workman P; Burrows F; Neckers L; Rosen N
Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the middle domains stabilizes Hsp90α dimer in a closed conformation with high affinity for p23.
Synoradzki K; Miszta P; Kazlauskas E; Mickevičiūtė A; Michailovienė V; Matulis D; Filipek S; Bieganowski P
Biol Chem; 2018 Mar; 399(4):337-345. PubMed ID: 29337688
[TBL] [Abstract][Full Text] [Related]
19. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.
Kovacs JJ; Murphy PJ; Gaillard S; Zhao X; Wu JT; Nicchitta CV; Yoshida M; Toft DO; Pratt WB; Yao TP
Mol Cell; 2005 May; 18(5):601-7. PubMed ID: 15916966
[TBL] [Abstract][Full Text] [Related]
20. ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation.
Kimura H; Yukitake H; Tajima Y; Suzuki H; Chikatsu T; Morimoto S; Funabashi Y; Omae H; Ito T; Yoneda Y; Takizawa M
Chem Biol; 2010 Jan; 17(1):18-27. PubMed ID: 20142037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
